$6.96
-0.17(-2.32%)
Mkt Cap $149M
$3.74
$9.00
52-Week Range
At a Glance
AI-generatedUnicycive Therapeutics reported significant operating and net losses in FY2025, with a notable year-over-year improvement in net income but a substantial decline in diluted EPS, reflecting the company's continued investment in clinical programs and commercial preparations amid persistent cash burn.
8-K
Unicycive Therapeutics announced its full year 2025 financial results, reporting a reduced net loss of $26.6 million and providing a business update on its lead drug candidate OLC, which has a PDUFA target action date of June 29, 2026.$149M
Market Cap
—
Revenue
-$40M
Net Income
Employees22
Fundamentals
How The Business Makes Money
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
Industry Biotechnology
Activity
Analyst View
Company Profile
CIK0001766140
ISINUS90466Y2028
CUSIP90466Y202
Phone650 351 4495
Address4300 El Camino Real, Los Altos, CA, 94022, US
SEC EDGAR